Two of the largest pharmaceutical companies in the obesity treatment space released second-quarter results on Aug 5, delivering contrasting headlines that underscore how differently investors can view scale versus valuation.
Q2 snapshot - Both companies disclosed quarterly results this morning. The following table outlines the key metrics observers are watching:
| Metric | Novo Nordisk (NVO) | Eli Lilly (LLY) |
|---|---|---|
| Q2 Revenue | $12.1B (+10.6% vs est.) | $22.97B (+11.7% vs est.) |
| Q2 EPS Beat / Miss | +21.9% beat | -5.2% miss (R&D charges) |
| Key Drug Revenue | Obesity care +16% | Mounjaro + Zepbound: $14.9B |
| FY Guidance | Raised (0% to -6% CER) | Raised to $85 67B |
| Price today | $45.18 (+2.02%) | $1,148.04 (+2.97%) |
The weight-loss drug battleground - The companies' product lines and clinical profiles define the competitive landscape. The table below captures reported efficacy, format, and status for the headline compounds mentioned in the results and accompanying commentary.
| Drug | Company | Mechanism | Weight Loss | Status |
|---|---|---|---|---|
| Zepbound (tirzepatide) | LLY | GLP-1 + GIP | ~22% / 72 wks | Dominant injectable |
| Wegovy (semaglutide) | NVO | GLP-1 | ~15% / 68 wks | Injectable + oral |
| Oral Wegovy pill | NVO | GLP-1 | ~14% / 64 wks | 5M+ U.S. prescriptions, record launch |
| Foundayo (oral) | LLY | GLP-1 | ~11% / 72 wks | 36K prescribers |
| Retatrutide | LLY | GLP-1 + GIP + Glucagon | ~22.6% | Phase 3, FDA filing Q1 2027 |
Lilly's retatrutide, a triple-hormone agonist, delivered positive Phase 3 data showing 22.6% weight loss in patients with severe obesity and has early-access availability open. If regulators approve the filing targeted for Q1 2027, the program could leapfrog current treatments according to the clinical data disclosed.
On the oral front, Novo Nordisk is reporting strong traction: oral Wegovy exceeded 5 million U.S. prescriptions and added 1 million prescriptions in a four-week span during its launch. In the oral GLP-1 format, Novo is ahead of Lilly's Foundayo in efficacy and volume.
Market share and access dynamics - Current prescription volumes favor Lilly in injectables: Zepbound injectable scripts exceed Wegovy's weekly U.S. volume by more than two times. Novo spent much of 2025 on the defensive, implementing guidance reductions, replacing its CEO, and cutting about 9,000 jobs.
The Medicare GLP-1 Bridge Program, launched July 1, provides both Wegovy and Zepbound at $50 per month to 20 million eligible Americans. Early program data indicate a strong patient preference for injectables, which benefits Lilly's market position. Separately, Novo initiated legal action in July, suing Lilly over alleged false advertising around efficacy comparisons and seeking a preliminary injunction to halt those ads.
Valuation comparison - Market capitalization and valuation multiples highlight a large divergence in how investors price the two firms:
| Metric | NVO | LLY | Edge |
|---|---|---|---|
| Market Cap | $210B | $995B | LLY (5x larger) |
| P/E (LTM) | 11.2x | 40.3x | NVO cheaper |
| P/E (Fwd) | 14.3x | 32.6x | NVO cheaper |
| EV/EBITDA | 8.0x | 29.1x | NVO cheaper |
| Gross Margin | 82.4% | 83.0% | Tie |
| ROIC | 39.5% | 45.0% | LLY higher |
| ROE | 59.8% | 107.6% | LLY (leveraged) |
| Debt/Equity | 63.3% | 139.0% | NVO safer |
| Dividend Yield | 3.9% | 0.6% | NVO wins |
| Fair Value Upside | +41.6% ($63.94) | +5.4% ($1,209) | NVO significantly undervalued |
| Analyst Target Upside | 2.7% | +16.5% | LLY (analysts bullish) |
| FY+1 Revenue Est. | $44.65B | $84.94B | LLY dominant scale |
Bull and bear cases
Novo Nordisk - Value narrative
- Bull: Novo is trading at a relatively low multiple of 11.2x LTM earnings; a fair value model shows roughly 41.6% upside to $63.94. Oral Wegovy is performing strongly by volume, and a year-to-date price decline of 12.5% may present an entry opportunity.
- Bear: U.S. injectable Wegovy revenue declined 22% at constant exchange rates amid pricing pressure and a 35% shift to self-pay. The company also faced a pipeline setback when ziltivekimab's ZEUS cardiovascular trial failed, and semaglutide is losing exclusivity in Canada and Brazil.
Eli Lilly - Growth narrative
- Bull: Lilly's revenue has scaled rapidly, with FY revenue at $65.18B compared with $28.32B five years earlier. Retatrutide's Phase 3 data and a planned filing in Q1 2027 could be transformational. The Medicare program expands access to 20 million patients and Lilly reports a ROIC of 45%.
- Bear: The shares trade at a premium, reflected in a 40.3x LTM P/E and limited fair value upside of 5.4%. Debt-to-equity is elevated at 139% and rising R&D spend could magnify leverage. Any clinical setback or policy change on pricing could compress Lilly's premium multiple.
Bottom line - The earnings releases reaffirm a clear split in investor choices: Lilly offers scale, current clinical leadership in injectables, and an extensive pipeline that includes retatrutide; Novo presents a lower-priced equity with meaningful modelled upside and a leadership position in oral GLP-1 prescriptions. Investors face a trade-off between a momentum-oriented exposure to Lilly and a contrarian, valuation-driven exposure to Novo.
Historical data referenced is limited to a 10-year window on a Pro+ plan as noted by the companies' reporting materials.